Caribou Stops Its Clinical Pipeline
Source-gap catch-up for a 6 October disclosure. Caribou Biosciences discontinued both clinical-stage allogeneic CAR-T programs, began a substantial workforce reduction and retained an adviser to explore strategic alternatives. The decision is a high-importance negative…
